A lawsuit was filed on behalf of investors in Argos Therapeutics Inc (NASDAQ:ARGS) shares over alleged securities laws violations and NASDAQ:ARGS investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/23/2017 -- An investor, who purchased shares of Argos Therapeutics Inc (NASDAQ:ARGS), filed a lawsuit in North Carolina over alleged violations of Federal Securities Laws by Argos Therapeutics Inc.
Investors who purchased shares of Argos Therapeutics Inc (NASDAQ:ARGS) have certain options and for certain investors are short and strict deadlines running. Deadline: May 15, 2017. NASDAQ:ARGS investors should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The plaintiff alleges that Argos Therapeutics Inc issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos Therapeutics Inc plummeted, damaging investors. In particular, the complaint alleges that Argos Therapeutics Inc issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017 Argos Therapeutics Inc announced that the Independent Data Monitoring Committee for the company's pivotal Phase 3 ADAPT clinical trial of rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of metastatic renal cell carcinoma (mRCC) has recommended that the study be discontinued for futility based on its planned interim data analysis. Shares of Argos Therapeutics Inc (NASDAQ:ARGS) dropped from $4.80 per share on February 21, 2017 to as low as $1.25 per share on February 22, 2017.
Those who purchased shares of Argos Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego